$AJANTPHARM

$AJANTPHARM RECEIVES USFDA EIR FOR PAITHAN FACILITY; INSPECTION CLASSIFIED AS VAI Ajanta Pharma has received the Establishment Inspection Report (EIR) from the USFDA for its Paithan manufacturing facility. The inspection has been classified as Voluntary Action Indicated (VAI). Receipt of the EIR signifies the inspection process has been successfully concluded. A VAI classification means the USFDA observed certain objectionable conditions, but they were not significant enough to warrant regulatory or enforcement action.